benefits of combining cd38 inhibitor with 5-amino-1mq Anti-CD38 antibody therapy for patients relapsed/refractory multiple myeloma: differential mechanisms action and recent clinical trial outcomes | Annals of Hematology Exploring NNMT: from metabolic pathways
Exploring NNMT: from metabolic pathways to therapeutic targets Archives of Pharmacal Research Springer Nature Link A Potent BCMA CD38 Dual Targeting Immunotherapy Combination Leads a New Paradigm in Second Line MM TreatmentMAJEStec 3 Study Heavily Released Nicotinamide N Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets Evolving Therapeutics in Multiple Myeloma Empower MM Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Pay in 4 interest-free payments of $7.25 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10



